Home|Journals|Articles by Year|Audio Abstracts
 

Research Article



INFLUENCE OF FERMENTED MELON SEED (OGIRI) PROTEIN ISOLATE ON POSTPRANDIAL BLOOD GLUCOSE LEVELS IN DIABETIC RATS

Anifat A Aloba-Lawal,O. E Babajide,Sulaimon Olayiwola Folami.




Abstract
Cited by 0 Articles

ABSTRACT
Abstract
Introduction
Diabetes mellitus is a prevalent endocrine disorder affecting millions worldwide, characterized by chronic hyperglycemia and associated with serious complications.
Aim
This study aimed to evaluate the anti-diabetic properties of Ogiri Protein Isolate (OPI) derived from fermented melon seeds (Citrullus vulgaris) and its effects on blood glucose levels, lipid profiles, and key organs in alloxan-induced diabetic rats.
Methods
Forty-two rats were divided into seven groups: positive control, negative control, diabetic group treated with 20% OPI, non-diabetic group treated with 20% OPI, diabetic group treated with 10% OPI, non-diabetic group treated with 10% OPI, and diabetic group treated with 80mg/kg Glibenclamide for 14 days. Fasting serum glucose levels, feed and water intake, weight gain, and plasma HDL-cholesterol and triglyceride levels were measured.
Results
OPI treatment significantly reduced fasting serum glucose levels in diabetic rats. There was a significant (p

Key words: Keywords: Ogiri Protein Isolate (OPI), anti-diabetic, Diabetes mellitus, Postprandial blood glucose and Alloxan.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.